Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Qiyu Biotech
company
About
Qiyu Biotech is an innovative macromolecular drug developer.
- 11 - 50
Details
- Last Funding Type
- Series A
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jul 1, 2017
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Qi Xiangdong, founder of Qiyu Bio, said: “Innovation is the starting and future of Qiyu Bio, and it is the core driving force of enterprise development. Qiyu Bio will use the first-class antibody technology platform to build superior biopharmaceutical pipelines and explore the field of biotherapy. A big breakthrough. With the development and improvement of the company, Qiyu will have core competitiveness in more fields.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
¥200M
Qiyu Biotech has raised a total of
¥200M
in funding over 2 rounds. Their latest funding was raised on
Dec 23, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 23, 2021 | Series B | ¥200M | 2 | — | — | Detail |
| Aug 13, 2019 | Series A | — | 2 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
4
Qiyu Biotech is funded by 4 investors.
Watson Investment
and Jundu Investment
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
|
|
Yes | Series A |
|
|
— | Series B |
Longmen Capital
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
